Department of Surgery and Science, Graduate School of Research Into Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, Toyama, Japan,
Breast Cancer. 2014 Jan;21(1):96-101. doi: 10.1007/s12282-012-0357-y. Epub 2012 Apr 17.
Some of the induced pluripotent stem cell (iPS cell)-inducing factors have been reported to be expressed in breast cancer. The aim of the present study was to examine the relationship between the expression of iPS cell-inducing factors and the prognosis of breast cancer patients.
In 100 breast cancer patients, the expression of c-MYC, KLF4, NANOG, OCT4, and SOX2 was determined by immunohistochemistry using a tissue microarray analysis.
Patients with strong expression of NANOG had significantly lower disease-free survival (DFS) and overall survival rates than those with weak expression of NANOG (P = 0.004 and 0.033, respectively). In contrast, patients with strong expression of KLF4 had better DFS (P = 0.014).
Strong expression of NANOG is an indicator of a poor prognosis for breast cancer patients, whereas KLF4 is a favorable prognostic indicator. Our results suggest that NANOG stimulates the growth and metastasis of breast cancer cells, whereas KLF4 inhibits these processes.
一些诱导多能干细胞（iPS 细胞）诱导因子已被报道在乳腺癌中表达。本研究旨在探讨 iPS 细胞诱导因子的表达与乳腺癌患者预后的关系。
采用组织微阵列分析，用免疫组织化学法检测 100 例乳腺癌患者中 c-MYC、KLF4、NANOG、OCT4 和 SOX2 的表达。
NANOG 强表达的患者无病生存率（DFS）和总生存率明显低于 NANOG 弱表达的患者（P=0.004 和 0.033）。相反，KLF4 强表达的患者 DFS 较好（P=0.014）。
NANOG 强表达是乳腺癌患者预后不良的指标，而 KLF4 是预后良好的指标。我们的结果表明，NANOG 刺激乳腺癌细胞的生长和转移，而 KLF4 抑制这些过程。
